

Public Health Link

from the Chief Medical Officer for Wales

Distribution:	As Appendix 2
From:	Chief Pharmaceutical Officer, Andrew Evans
Date:	26 September 2019
Reference:	CEM/CPhA/2019/22
Category:	Class 2 - Action within 48 hours
Title:	Drug Alert Class 2 - Martindale Pharmaceuticals Ltd (Ethypharm Group) Bisacodyl 10mg Suppositories
For Action by:	<p>Dispensing General Practitioners – please ensure this message is seen by all working in your dispensary and retain a copy in your 'locum information pack'</p> <p>Community Pharmacists</p> <p>Hospital pharmacies</p> <p>Chief Pharmacists</p>
For Information:	See Annex 2 – Distribution List
What is this about:	Full details are set out below.
Why has it been sent:	For your information, action and to pass on to colleagues.

Issue:

Martindale Pharmaceuticals Limited is recalling a batch of Bisacodyl 10mg Suppositories due to an issue with homogeneity. This may result in individual suppositories containing too little or too much active substance.

Full details of the drug alert are included in the attached PDF file.

Appendix 1

- To: Chief Executives of Health Boards and NHS Trusts
- To: Medical Directors of Health Boards
- To: Nurse Directors Health Boards
- To: Directors of Public Health
- To: Hospital Principals and Chief Pharmacists to action as per alert

To: **NHS Wales Shared Services Partnership to forward to:**

Dispensing General Practitioners

Community Pharmacists

Deputising services

HB Prescribing Advisers

Independent/Private clinics and Hospitals and Hospices throughout Wales



DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours
Pharmacy Level Recall

Date: 23 September 2019

EL (19)A/22

Our Ref: MDR 58-09/19

Dear Healthcare Professional,

Martindale Pharmaceuticals Limited

Bisacodyl 10mg Suppositories

PL 0156/0045

Batch Number	Expiry Date	Pack Size	First Distributed
BUK901	APR 2022	1 x 12	17 Jun 2019

Brief description of the problem

Martindale Pharmaceuticals Limited is recalling the above batch due to an issue with homogeneity. This may result in individual suppositories containing too little or too much active substance.

Advice for healthcare professionals

Please quarantine all remaining stock of the above batch and return it to your supplier using your supplier's approved process.

Company contacts for further information

For stock control enquiries please email licensed@ethypharm.com

For medical information enquiries please email medinfo@ethypharm.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS Regional teams are asked to forward this to relevant clinics, dispensing general practitioners and community pharmacists.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574